The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

<h4>Background</h4>Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab trea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Angelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, Carmen Crespo, Cesar Mendiola, Rocío López-Vacas, Julia Berges-Soria, Isabel Álvarez López, Mireia Margeli, Juan L Bayo Calero, Xavier González Farre, Ana Santaballa, Eva M Ciruelos, Ruth Afonso, Juan Lao, Gustavo Catalán, José V Álvarez Gallego, José Miramón López, Francisco J Salvador Bofill, Manuel Ruiz Borrego, Enrique Espinosa, Juan A Fresno Vara, Pilar Zamora
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/96570f731e5b47eda63fe7f906eaa872
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.

Ejemplares similares